Korean J Anesthesiol.
2006 Nov;51(5):519-527. 10.4097/kjae.2006.51.5.519.
New Inotropic Agent-Levosimendan
- Affiliations
-
- 1Department of Anesthesiology and Pain Medicine, University of Ulsan College of Medicine, Seoul, Korea. icchoi@amc.seoul.kr
- KMID: 2034385
- DOI: http://doi.org/10.4097/kjae.2006.51.5.519
Abstract
- Several clinical studies suggest substantial limitations of currently available positive inotropic substances, including beta1-adrenoceptor agonists and phosphodiesterase III inhibitors. Levosimendan, a myofilament calcium sensitizer with inotropic effects, increases myocardial performance without substantial changes in oxygen consumption and with neutral effects on heart rhythm. In addition, levosimendan has vasodilatory effects that are achieved by stimulation of adenosine triphosphate-dependent potassium channels. This review article briefly discusses the pharmacology of levosimendan and evaluates current available evidence to assess the safety and efficacy of levosimendan.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Mechanism of the Positive Inotropic Actions of Quaternary Ammonium Compounds
- Do Presynaptic alpha-Adrenoceptors Exist in the Cardioaccelerator Nerve of Cold-blooded Animals?
- Levosimendan Reduces Lung Injury in a Canine Model of Cardiopulmonary Bypass
- Effects of Inotropic Drugs on Mechanical Function and Oxygen Balance in Postischemic Canine Myocardium: Comparison of Dobutamine, Epinephrine, Amrinone, and Calcium Chloride
- Inotropic Agents
